CN103874690B - 含酰肼的核运输调节剂及其用途 - Google Patents

含酰肼的核运输调节剂及其用途 Download PDF

Info

Publication number
CN103874690B
CN103874690B CN201280047939.2A CN201280047939A CN103874690B CN 103874690 B CN103874690 B CN 103874690B CN 201280047939 A CN201280047939 A CN 201280047939A CN 103874690 B CN103874690 B CN 103874690B
Authority
CN
China
Prior art keywords
compound
formula
trifluoromethyl
bis
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280047939.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103874690A (zh
Inventor
V·P·桑达纳亚卡
S·沙查姆
D·麦考利
S·谢克特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karyopharm Therapeutics Inc
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Priority to CN202311190454.5A priority Critical patent/CN117229268A/zh
Priority to CN201610414957.XA priority patent/CN106083827B/zh
Priority to CN201910730981.8A priority patent/CN110372672B/zh
Priority to CN201910734865.3A priority patent/CN110372673B/zh
Publication of CN103874690A publication Critical patent/CN103874690A/zh
Application granted granted Critical
Publication of CN103874690B publication Critical patent/CN103874690B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hydrogenated Pyridines (AREA)
CN201280047939.2A 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途 Active CN103874690B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202311190454.5A CN117229268A (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201610414957.XA CN106083827B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201910730981.8A CN110372672B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201910734865.3A CN110372673B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161513432P 2011-07-29 2011-07-29
US201161513428P 2011-07-29 2011-07-29
US61/513,428 2011-07-29
US61/513,432 2011-07-29
US201261610178P 2012-03-13 2012-03-13
US61/610,178 2012-03-13
US201261653588P 2012-05-31 2012-05-31
US61/653,588 2012-05-31
US201261654651P 2012-06-01 2012-06-01
US61/654,651 2012-06-01
PCT/US2012/048319 WO2013019548A1 (en) 2011-07-29 2012-07-26 Hydrazide containing nuclear transport modulators and uses thereof

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN201910730981.8A Division CN110372672B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN202311190454.5A Division CN117229268A (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201610414957.XA Division CN106083827B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201910734865.3A Division CN110372673B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途

Publications (2)

Publication Number Publication Date
CN103874690A CN103874690A (zh) 2014-06-18
CN103874690B true CN103874690B (zh) 2016-07-06

Family

ID=46634546

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201280047939.2A Active CN103874690B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201910730981.8A Active CN110372672B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN202311190454.5A Pending CN117229268A (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201910734865.3A Active CN110372673B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201610414957.XA Active CN106083827B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201910730981.8A Active CN110372672B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN202311190454.5A Pending CN117229268A (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201910734865.3A Active CN110372673B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途
CN201610414957.XA Active CN106083827B (zh) 2011-07-29 2012-07-26 含酰肼的核运输调节剂及其用途

Country Status (35)

Country Link
US (9) US9079865B2 (enExample)
EP (3) EP3333164B1 (enExample)
JP (3) JP6005740B2 (enExample)
KR (7) KR20210083380A (enExample)
CN (5) CN103874690B (enExample)
AR (1) AR087342A1 (enExample)
AU (6) AU2012290454B2 (enExample)
BR (1) BR112014001934B1 (enExample)
CA (1) CA2842362C (enExample)
CL (2) CL2014000225A1 (enExample)
CO (1) CO6960539A2 (enExample)
CY (2) CY1119783T1 (enExample)
DK (2) DK3333164T3 (enExample)
EA (1) EA201490407A1 (enExample)
ES (2) ES2954991T3 (enExample)
FR (1) FR21C1042I2 (enExample)
GE (1) GEP201706616B (enExample)
HR (1) HRP20180014T1 (enExample)
HU (2) HUE036058T2 (enExample)
LT (2) LT2736887T (enExample)
LU (1) LUC00219I2 (enExample)
ME (1) ME02936B (enExample)
MX (2) MX349712B (enExample)
NL (1) NL301119I2 (enExample)
NO (1) NO2021033I1 (enExample)
PE (1) PE20141170A1 (enExample)
PL (2) PL3333164T3 (enExample)
PT (1) PT2736887T (enExample)
RS (1) RS56823B1 (enExample)
SI (1) SI2736887T1 (enExample)
SM (1) SMT201800171T1 (enExample)
TW (1) TWI574957B (enExample)
UA (1) UA115532C2 (enExample)
WO (1) WO2013019548A1 (enExample)
ZA (1) ZA201401223B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083827A (zh) * 2011-07-29 2016-11-09 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
US10335393B2 (en) 2012-05-09 2019-07-02 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US10407405B2 (en) 2013-06-21 2019-09-10 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10519139B2 (en) 2014-08-15 2019-12-31 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
KR102022715B1 (ko) * 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
EP2805713B1 (en) 2012-01-18 2018-10-10 Bioneer Corporation Magnetic nanoparticle-samirna complex and method for preparing same
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
MX379228B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulación de la hemoglobina.
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
AU2014284835B2 (en) 2013-07-05 2017-08-10 Bioneer Corporation Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
PL3018208T3 (pl) 2013-07-05 2020-09-21 Bioneer Corporation Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6527149B2 (ja) * 2013-11-28 2019-06-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ベータ−サラセミアの処置のための方法及び医薬組成物
ES2984979T3 (es) 2014-04-04 2024-10-31 Bioneer Corp Oligo ARN de doble cadena y composición farmacéutica que comprende el mismo para la prevención o tratamiento de fibrosis o enfermedades respiratorias
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2018050801A1 (en) 2016-09-16 2018-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
CN106831617A (zh) * 2017-01-17 2017-06-13 广州市闻皓生物科技有限公司 一种Selinexor中间体的合成工艺
US20200222410A1 (en) * 2017-04-13 2020-07-16 Brown University Nucleocytoplasmic regulator of autophagy-associated transcription factors
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN108947982A (zh) * 2018-08-16 2018-12-07 刘璐 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
WO2020191140A1 (en) 2019-03-20 2020-09-24 Johnson Matthey Public Limited Company Co-crystal forms of selinexor
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
MX2021013211A (es) * 2019-05-01 2022-03-11 Karyopharm Therapeutics Inc Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2021163338A1 (en) 2020-02-11 2021-08-19 Karyopharm Therapeutics Inc. Xpo1 inhibitors for use in treating cancer
CA3171979A1 (en) 2020-03-27 2021-09-30 Josep Bassaganya-Riera Plxdc2 ligands
WO2021202745A1 (en) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Treatment of covid-19 with a sine compound
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021252900A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2021252905A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in diffuse large b-cell lymphoma patients
WO2021252874A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Xpo1 inhibitors for use in treating cancer
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用
WO2022232417A1 (en) 2021-04-28 2022-11-03 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2022246065A1 (en) 2021-05-19 2022-11-24 Karyopharm Therapeutics Inc. Calb1 biomarker in the treatment of de-differentiated liposarcoma using xpo1 inhibitors, such as selinexor
WO2023172855A2 (en) * 2022-03-07 2023-09-14 Kaohsiung Medical University Methods for treating hepatitis b virus infection
CN116625976B (zh) * 2023-04-10 2025-11-21 南京农业大学 一种微生物浓度的监测系统及方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
JPS5661360A (en) * 1979-10-25 1981-05-26 Teijin Ltd 1-substituted imidazole derivative and its preparation
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
EP1544197A1 (en) 1996-04-04 2005-06-22 Shionogi & Co., Ltd. Intermediates for cephem compounds
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
CN101817784B (zh) 1996-04-25 2012-02-01 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
US7569724B2 (en) 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
KR20100107509A (ko) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
MXPA05004505A (es) * 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
MX2007001634A (es) 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
USRE46792E1 (en) 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
WO2007102580A1 (ja) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
CN101443330B (zh) 2006-06-13 2012-12-19 上海海和药物研究开发有限公司 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
JP2010519337A (ja) * 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
JP2012532889A (ja) 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
KR102022715B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action;Tine Van Neck et al;《Bioorganic & Medicinal Chemistry》;20080920;第16卷;9487-9497,第9489页Figure 3、第9490－9491页2.4部分 *
具有生物活性的酰肼衍生物的研究进展;柯少勇 等;《有机化学》;20101231;第30卷(第12期);1820-1830，第1820页第1段 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10544108B2 (en) 2011-07-29 2020-01-28 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
CN117229268A (zh) * 2011-07-29 2023-12-15 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
CN110372673B (zh) * 2011-07-29 2023-10-03 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
CN106083827B (zh) * 2011-07-29 2019-09-17 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
CN110372672A (zh) * 2011-07-29 2019-10-25 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
CN110372673A (zh) * 2011-07-29 2019-10-25 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
CN106083827A (zh) * 2011-07-29 2016-11-09 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
US12291508B2 (en) 2011-07-29 2025-05-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
US11787771B2 (en) 2011-07-29 2023-10-17 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
CN110372672B (zh) * 2011-07-29 2023-09-29 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
US11034660B2 (en) 2011-07-29 2021-06-15 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
US10925859B2 (en) 2012-05-09 2021-02-23 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US10617677B2 (en) 2012-05-09 2020-04-14 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US11318120B2 (en) 2012-05-09 2022-05-03 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US10335393B2 (en) 2012-05-09 2019-07-02 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US11945794B2 (en) 2013-06-21 2024-04-02 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11124493B2 (en) 2013-06-21 2021-09-21 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10407405B2 (en) 2013-06-21 2019-09-10 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10519139B2 (en) 2014-08-15 2019-12-31 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
US11753401B2 (en) 2014-08-15 2023-09-12 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
US11746102B2 (en) 2014-08-15 2023-09-05 Karyopharm Therapeutics Inc. Polymorphs of selinexor
US11807629B2 (en) 2014-08-15 2023-11-07 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
US11078190B2 (en) 2014-08-15 2021-08-03 Karyopharm Therapeutics Inc. Polymorphs of selinexor
US12371420B2 (en) 2014-08-15 2025-07-29 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy

Also Published As

Publication number Publication date
US20200339521A1 (en) 2020-10-29
KR102022716B1 (ko) 2019-09-18
CN106083827A (zh) 2016-11-09
US20160304472A1 (en) 2016-10-20
AU2012290454B2 (en) 2016-05-05
US9206158B2 (en) 2015-12-08
JP6005740B2 (ja) 2016-10-12
JP6675431B2 (ja) 2020-04-01
KR20250008805A (ko) 2025-01-15
SMT201800171T1 (it) 2018-07-17
GEP201706616B (en) 2017-02-10
CN110372673A (zh) 2019-10-25
AU2020203121A1 (en) 2020-05-28
LTC2736887I2 (enExample) 2022-10-25
CO6960539A2 (es) 2014-05-30
US20140235653A1 (en) 2014-08-21
US12291508B2 (en) 2025-05-06
US20180127384A1 (en) 2018-05-10
LTPA2021007I1 (enExample) 2021-08-25
US10173987B2 (en) 2019-01-08
DK3333164T3 (da) 2023-09-18
US11034660B2 (en) 2021-06-15
AU2016210682A1 (en) 2016-08-18
NL301119I1 (enExample) 2021-08-04
ES2655645T3 (es) 2018-02-21
JP2014521652A (ja) 2014-08-28
US20190330164A1 (en) 2019-10-31
JP2018111713A (ja) 2018-07-19
CY1119783T1 (el) 2018-06-27
CN110372673B (zh) 2023-10-03
AR087342A1 (es) 2014-03-19
KR20230042129A (ko) 2023-03-27
NZ621904A (en) 2016-05-27
MX349712B (es) 2017-08-09
ZA201401223B (en) 2022-03-30
US10544108B2 (en) 2020-01-28
BR112014001934A2 (pt) 2017-02-21
CL2015001257A1 (es) 2015-09-21
US11787771B2 (en) 2023-10-17
CN110372672B (zh) 2023-09-29
PL3333164T3 (pl) 2023-12-18
CY2021028I2 (el) 2022-03-24
AU2016210682B2 (en) 2018-04-19
JP6309057B2 (ja) 2018-04-11
EP2736887A1 (en) 2014-06-04
ME02936B (me) 2018-04-20
FR21C1042I2 (fr) 2022-09-02
US20220073478A1 (en) 2022-03-10
EP4234545A2 (en) 2023-08-30
RS56823B1 (sr) 2018-04-30
JP2017036287A (ja) 2017-02-16
WO2013019548A1 (en) 2013-02-07
CN117229268A (zh) 2023-12-15
US9714226B2 (en) 2017-07-25
AU2018202441A1 (en) 2018-04-26
NO2021033I1 (no) 2021-09-06
EP2736887B1 (en) 2017-10-18
HUE036058T2 (hu) 2018-06-28
EP3333164A1 (en) 2018-06-13
CY2021028I1 (el) 2022-03-24
CA2842362A1 (en) 2013-02-07
HK1256745A1 (en) 2019-10-04
MX378433B (es) 2025-03-11
LT2736887T (lt) 2018-02-12
EA201490407A1 (ru) 2014-05-30
HUS2100030I1 (hu) 2021-09-28
HK1198477A1 (en) 2015-05-08
MX2014001181A (es) 2014-07-14
KR20240060688A (ko) 2024-05-08
ES2954991T3 (es) 2023-11-28
KR20190045399A (ko) 2019-05-02
EP3333164B1 (en) 2023-06-07
CN103874690A (zh) 2014-06-18
US20150274698A1 (en) 2015-10-01
NL301119I2 (nl) 2021-09-15
LUC00219I2 (enExample) 2022-10-07
FR21C1042I1 (enExample) 2021-11-19
DK2736887T3 (en) 2018-01-02
PT2736887T (pt) 2018-01-15
AU2024202868A1 (en) 2024-05-23
KR20140066179A (ko) 2014-05-30
PL2736887T3 (pl) 2018-03-30
CL2014000225A1 (es) 2014-12-05
UA115532C2 (uk) 2017-11-27
US9079865B2 (en) 2015-07-14
TWI574957B (zh) 2017-03-21
AU2020203121B2 (en) 2022-02-17
US8999996B2 (en) 2015-04-07
HRP20180014T1 (hr) 2018-04-20
KR20210083380A (ko) 2021-07-06
NZ719623A (en) 2017-12-22
US20140364408A1 (en) 2014-12-11
EP4234545A3 (en) 2023-09-06
KR102136768B1 (ko) 2020-07-23
US20240279188A1 (en) 2024-08-22
CA2842362C (en) 2020-06-16
TW201311666A (zh) 2013-03-16
CN106083827B (zh) 2019-09-17
SI2736887T1 (en) 2018-04-30
CN110372672A (zh) 2019-10-25
KR20200088518A (ko) 2020-07-22
AU2022203265A1 (en) 2022-06-02
AU2012290454A1 (en) 2014-03-20
PE20141170A1 (es) 2014-09-16
AU2018202441B2 (en) 2020-02-13
BR112014001934B1 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
CN103874690B (zh) 含酰肼的核运输调节剂及其用途
HK1198477B (en) Hydrazide containing nuclear transport modulators and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant